IMCD shares slip after Jefferies downgrade to Hold
IMCD NV shares dropped 1.5% to €101.55 after Jefferies analyst David Kerstens lowered his recommendation on the specialty chemicals distributor from Buy to Hold and reduced his price target to €115 from €122, citing lower earnings estimates.
Kerstens argued that the expected return to moderate, volume-led growth and margin improvement is already mostly priced into the stock, which has rallied strongly and is now close to its 52-week high of €105.55.
The Jefferies note also said the inflation-driven pricing support that had benefited the sector is diminishing, leaving the market in what it described as a 'waiting for volumes' phase.
The assessment followed IMCD’s first-nine-months 2026 results by less than a week. Those figures showed EBITA rising 11% at constant currency to €425 million and organic EBITA growth of 14% in Q3. Kerstens considered the numbers solid but not enough to support a more optimistic view at current valuations.
The downgrade formed part of a wider sector review: Jefferies also moved peer Azelis, one of IMCD’s closest European competitors, to Hold, indicating that the cautious stance stems from industry-wide trends rather than company-specific problems at IMCD.
The two actions increased selling pressure across European specialty chemical distribution stocks. Before today, IMCD had 11 Buy ratings, 2 Hold ratings and 1 Sell rating, so Jefferies’ change represented a notable shift in the analyst consensus.
In the broader market, the decline stood out because global equities were higher: the S&P 500 was up about 1.0% and the Nasdaq nearly 1.9%, offering no macroeconomic support for the selloff.
A prominent analyst downgrade, a lower price target and sector-wide caution over the pace of volume recovery were enough to drive IMCD lower despite an otherwise positive market backdrop.
This article was created with AI assistance and reviewed by an editor; further information is available in the terms and conditions.